Ropistim/romigrastim is generally effective after a few injections

Romiplostim is a drug used to treat idiopathic thrombocytopenia (ITP), usually in patients who have not responded to other treatments. It increases platelet counts bystimulating megakaryocytes in the bone marrow to produce platelets. Due to advances in molecular biology, biochemistry, and pharmacology, ropruprim is one of many new molecules that are available for clinical use. It is specifically designed to increase platelet production by activating TPO receptors while avoiding the immunogenicity of previous drugs.

In general, the frequency of use of Roprostim is once a week, and the dosage will be adjusted based on the patient's platelet count. When starting treatment, doctors usually determine the initial dose based on the patient's initial platelet levels, and then adjust the dose based on the response of the platelet count during subsequent follow-up visits. This personalized adjustment helps ensure patients receive the best possible treatment results while reducing possible side effects. Early phase I/II studies show the promise of these drugs in ITP. A subsequent phase III randomized controlled study, one of the largest clinical studies conducted in ITP, confirmed these findings, with 80% of patients responding to loproprimostat.

Effective treatment usually requires continuous injections, and it may take weeks to months to see significant results initially. In some cases, patients may see significant improvements in platelet levels after just a few shots, while others may need longer treatment to achieve ideal platelet counts. Therefore, there is no fixed answer as to how many injections are effective and must be evaluated based on the patient's condition.